Prescribed Beyond Boundaries: Unpacking the Clinical and Regulatory Tensions Driving Modafinil's Off-Label Expansion
Modafinil holds FDA approval for three specific sleep-wake disorders, yet clinicians across the United States routinely prescribe it for psychiatric conditions ranging from treatment-resistant depression to bipolar fatigue. This article examines the evidentiary landscape behind these unapproved uses, the regulatory framework that permits prescriber discretion, and the ethical tensions that arise when clinical pragmatism outpaces rigorous proof.